The Truth-O-Meter Says:
Bachmann

"Scientists tell us that we could have a cure in 10 years for Alzheimer's" were it not for "overzealous regulators, excessive taxation and greedy litigators."

Michele Bachmann on Saturday, March 16th, 2013 in a speech at CPAC

Michele Bachmann says Alzheimer's disease could be cured if not for government regulation, taxes and lawyers

Are bureaucrats, high taxation and trial lawyers keeping America from tackling Alzheimer’s disease? Rep. Michele Bachmann, R-Minn., said they are during a speech to CPAC, the annual conservative conference.


After recalling the history of vaccinations against polio, Bachmann said, "We have another disease ... that's hurting us today. It's called Alzheimer's. ... There is no known treatment for Alzheimer's on the horizon. … Scientists tell us that we could have a cure in 10 years for Alzheimer's, if we'd only put our mind to it. So why aren't we seeking to cure diseases like Alzheimer's, or diabetes, juvenile diabetes, heart disease, cancer, Parkinson's disease? How did we possibly get to this point of political malpractice? Because our government, proclaiming to care so much, has created a cadre of overzealous regulators, excessive taxation and greedy litigators. That's not caring. It's time we care."


We wondered if it was accurate for Bachmann to say that "scientists tell us that we could have a cure in 10 years for Alzheimer's" were it not for "overzealous regulators, excessive taxation and greedy litigators." So we checked with a variety of Alzheimer’s researchers and policy experts. (Bachmann’s office did not respond to an inquiry for this article.)


We found a strong consensus among Alzheimer’s disease experts that Bachmann’s factors are either minor obstacles or not obstacles at all. Instead, they cited two primary concerns -- insufficient funding and the complexity of the disease itself.


First, let’s look at funding.


"The only thing keeping us from developing successful treatments for Alzheimer's disease is the lack of adequate funding for research from NIH and other federal agencies," said Robert A. Stern, a neurologist and neurosurgeon, as well as a director of the Alzheimer's Disease Center at the Boston University School of Medicine. "That has nothing to do with her naive and scary statements. It only has to do with Congress deciding that it is worth spending money on."


We should note that the Obama administration did shift $50 million into Alzheimer’s research for fiscal year 2012 and requested an additional $80 million for fiscal year 2013. It also dedicated nearly $80 million in stimulus money to Alzheimer’s for each of two fiscal years, 2009 and 2010.


Still, these temporary increases were not built into the ongoing baseline. The baseline level has remained fairly constant since Obama took office, at about $450 million a year. And that amount is due to be cut back this year due to the across-the-board cuts known as sequestration.


"After many years of expansion under the Clinton administration, the budget for the National Institutes of Health has remained relatively stagnant for more than a decade," said Deborah E. Barnes, an Alzheimer’s specialist at the University of California, San Francisco. "This has put the squeeze on scientists. In the past, the top 25 percent to 30 percent of research proposals would receive funding. Now it is the top 5 percent to 10 percent. This means that a lot of really good research is not being funded, and our progress toward finding a cure for Alzheimer's and other important disorders has been slowed. The funding for NIH comes from taxpayer dollars, so excessive taxation is clearly not the problem."

 

The other key obstacle our experts cited is the nature of the disease itself.


If Bachmann is looking for diseases that have been sidetracked by bureaucratic or regulatory hurdles, "Alzheimer's is about the worst example she could give," said R. Alta Charo, a bioethicist at the University of Wisconsin.


The disease, she said, "develops over years from causes still unclear. The real dilemma for Alzheimer's drug trials -- or for trials of any disease that develops slowly with symptoms that may easily be due to other diseases and which may be of varying intensity -- is that there is no form of standard clinical trial that can test interventions and cures within a reasonable time frame."


As a result, she said, the FDA has allowed various kinds of abbreviated trials that don’t evaluate progress in slowing or reversing the disease itself. Instead, they track "surrogate markers" -- indicators that seem to suggest that a drug is helping. But not all markers translate over time into clinical benefit, she said.


Such practical challenges have produced a trail of broken hopes. In a 2012 "setbacks report" on Alzheimer’s drug research, the Pharmaceutical Research and Manufacturers of America, the nation’s leading trade group for drugmakers, tallied 101 "failed" Alzheimer’s drugs since 1998, with a rate of 34 setbacks for every drug approved. And even the medicines that have won approval have provided symptomatic relief to some patients, rather than actually rolling back the disease itself.


One might expect PhRMA, one of the most influential pro-business lobbying groups in Washington, to applaud the notion that overzealous regulation, high taxation and aggressive plaintiffs attorneys are curbing the industry’s efforts. But in the case of Alzheimer’s, at least, the "setbacks report" doesn’t even touch on those issues.


So what does the report point to instead? It talks largely about the practical challenges of dealing with a complicated disease.


"Scientists still do not fully understand the underlying causes and mechanisms of the disease, particularly when it comes to separating potential causes from effects of the disease. This makes selection of viable targets for new medicines very difficult," the report says. It adds that "the limited utility of current models of the human disease is a huge barrier in preclinical testing of drug candidates."


The difficulty of finding testable indicators of the disease, the report continues, "makes it particularly challenging to evaluate, enroll, follow up, and retain patients in clinical studies. Ultimately this leads to long and very expensive clinical trials."


Our ruling


Bachmann said that "scientists tell us that we could have a cure in 10 years for Alzheimer's" were it not for "overzealous regulators, excessive taxation and greedy litigators." The 10-year goal may or may not be plausible, but if it’s not, there’s wide agreement that the three factors Bachmann mentioned are not the primary obstacles.


Instead, researchers pointed to stagnant funding and the fact that Alzheimer’s is a particularly tricky disease to research, given its slow and stealthy advances. If Bachmann was looking to score points about bureaucracy and taxation, she has made a particularly poor choice of case study. Bachmann has taken a popular theme and assigned it to a complicated health condition, simply to score political points. The experts say her claim is unfounded. We rate her claim Pants on Fire!

Advertisement
About this statement:

Published: Wednesday, March 20th, 2013 at 4:55 p.m.

Subjects: Government regulation, Health Care, Regulation, Science

Sources:

Michele Bachmann, remarks to the CPAC conference, March 16, 2013


National Institutes of Health, "Estimates of Funding for Various Research, Condition, and Disease Categories," Feb. 13, 2012


Department of Health and Human Services, "We can’t wait: Administration announces new steps to fight Alzheimer’s disease," Feb. 7, 2012


Department of Health and Human Services, "Fact Sheet: We Can’t Wait: Taking Action on Alzheimer’s Disease," Feb. 7, 2012


Pharmaceutical Research and Manufacturers of America, "Researching Alzheimer’s Medicines: Setbacks and Stepping Stones," 2012


Email interview with Erin Heath, associate director of the office of government relations for the American Association for the Advancement of Science, March 20, 2013


Email interview with Robert A. Stern, director of the Alzheimer's Disease Center at the Boston University School of Medicine, March 20, 2013


Email interview with R. Alta Charo, bioethicist at the University of Wisconsin, March 18, 2013


Email interview with Deborah E. Barnes, Alzheimer’s specialist at the University of California, San Francisco, March 20, 2013


Email interview with Gad A. Marshall, neurologist at Harvard Medical School and associate medical director of clinical trials at the Center for Alzheimer Research and Treatment at Brigham and Women's Hospital, March 20, 2013

Written by: Louis Jacobson
Researched by: Louis Jacobson
Edited by: Angie Drobnic Holan

How to contact us:

We want to hear your suggestions and comments.

For tips or comments on our Obameter and our GOP-Pledge-O-Meter promise databases, please e-mail the Obameter. If you are commenting on a specific promise, please include the wording of the promise.

For comments about our Truth-O-Meter or Flip-O-Meter items, please e-mail the Truth-O-Meter. We’re especially interested in seeing any chain e-mails you receive that you would like us to check out. If you send us a comment, we'll assume you don't mind us publishing it unless you tell us otherwise.

Browse The Truth-O-MeterTM:
Subscribe: